{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:44:50Z","timestamp":1792010690363,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011851","name":"Kom op tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12967-019-2051-8","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T08:04:13Z","timestamp":1567670653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":120,"title":["Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3789-6256","authenticated-orcid":false,"given":"Teofila","family":"Seremet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanina","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Planken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Njimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Delaunoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim","family":"El Housni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Awada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Katharina","family":"Schwarze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Keyaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Everaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Lienard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Del Marmol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Heimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Neyns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"key":"2051_CR1","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14:463\u201382. \n                    https:\/\/doi.org\/10.1038\/nrclinonc.2017.43\n                    \n                  .","journal-title":"Nat Rev Clin Oncol"},{"key":"2051_CR2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJM, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb\u00e9 C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1003466\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"2051_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebb\u00e9 C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1412082\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"2051_CR4","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A, KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521\u201332. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1503093\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"2051_CR5","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","volume":"34","author":"AI Daud","year":"2016","unstructured":"Daud AI, Wolchok JD, Robert C, Hwu W-J, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol. 2016;34:4102\u20139. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.67.2477\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"2051_CR6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1504030","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015. \n                    https:\/\/doi.org\/10.1056\/nejmoa1504030\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"2051_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40425-018-0344-8","volume":"6","author":"C Morrison","year":"2018","unstructured":"Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Lenzo FL, Omilian A, Bshara W, Zibelman M, Ghatalia P, Dragnev K, Shirai K, Madden KG, Tafe LJ, Shah N, Kasuganti D, de la Cruz-Merino L, Araujo I, Saenger Y, Bogardus M, Villalona-Calero M, Diaz Z, Day R, Eisenberg M, Anderson SM, Puzanov I, Galluzzi L, Gardner M, Ernstoff MS. Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. J Immunother Cancer. 2018;6:32. \n                    https:\/\/doi.org\/10.1186\/s40425-018-0344-8\n                    \n                  .","journal-title":"J Immunother Cancer"},{"key":"2051_CR8","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SKN, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih IM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang T-L, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.3007094\n                    \n                  .","journal-title":"Sci Transl Med"},{"key":"2051_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/CMR.0000000000000224","volume":"26","author":"M Schreuer","year":"2016","unstructured":"Schreuer M, Meersseman G, van Den Herrewegen S, Jansen Y, Seremet T, Bott A, Chevolet I, Wilgenhof S, Maertens G, Neyns B. Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma. Melanoma Res. 2016;26:157\u201363. \n                    https:\/\/doi.org\/10.1097\/CMR.0000000000000224\n                    \n                  .","journal-title":"Melanoma Res"},{"key":"2051_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12967-016-0852-6","volume":"14","author":"M Schreuer","year":"2016","unstructured":"Schreuer M, Meersseman G, Van Den Herrewegen S, Jansen Y, Chevolet I, Bott A, Wilgenhof S, Seremet T, Jacobs B, Buyl R, Maertens G, Neyns B. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF\/MEK inhibitors. J Transl Med. 2016;14:95. \n                    https:\/\/doi.org\/10.1186\/s12967-016-0852-6\n                    \n                  .","journal-title":"J Transl Med"},{"key":"2051_CR11","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1373\/clinchem.2017.281543","volume":"64","author":"V Haselmann","year":"2018","unstructured":"Haselmann V, Gebhardt C, Brechtel I, Duda A, Czerwinski C, Sucker A, Holland-Letz T, Utikal J, Schadendorf D, Neumaier M. Liquid profiling of circulating tumor DNA in plasma of melanoma patients for companion diagnostics and monitoring of BRAF inhibitor therapy. Clin Chem. 2018;64:830\u201342. \n                    https:\/\/doi.org\/10.1373\/clinchem.2017.281543\n                    \n                  .","journal-title":"Clin Chem"},{"key":"2051_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1373\/clinchem.2014.230235","volume":"61","author":"MF Sanmamed","year":"2015","unstructured":"Sanmamed MF, Fern\u00e1ndez-Land\u00e1zuri S, Rodr\u00edguez C, Z\u00e1rate R, Lozano MD, Zubiri L, Perez-Gracia JL, Mart\u00edn-Algarra S, Gonz\u00e1lez A. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem. 2015;61:297\u2013304. \n                    https:\/\/doi.org\/10.1373\/clinchem.2014.230235\n                    \n                  .","journal-title":"Clin Chem"},{"key":"2051_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/CMR.0000000000000415","volume":"28","author":"T Seremet","year":"2018","unstructured":"Seremet T, Planken S, Schreuer M, Jansen Y, Delaunoy M, El Housni H, Lienard D, Del Marmol V, Heimann P, Neyns B. Illustrative cases for monitoring by quantitative analysis of BRAF\/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy. Melanoma Res. 2018;28:65\u201370. \n                    https:\/\/doi.org\/10.1097\/CMR.0000000000000415\n                    \n                  .","journal-title":"Melanoma Res"},{"key":"2051_CR14","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","volume":"28","author":"JH Lee","year":"2017","unstructured":"Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, Guminski A, Jakrot V, Scolyer RA, Mann GJ, Kefford RF, Carlino MS, Rizos H. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol. 2017;28:1130\u20136. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx026\n                    \n                  .","journal-title":"Ann Oncol"},{"key":"2051_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx212","author":"L Cabel","year":"2017","unstructured":"Cabel L, Riva F, Servois V, Livartowski A, Daniel C, Rampanou A, Lantz O, Romano E, Milder M, Buecher B, Piperno-Neumann S, Bernard V, Baulande S, Bieche I, Pierga JY, Proudhon C, Bidard FC. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. Ann Oncol. 2017. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx212\n                    \n                  .","journal-title":"Ann Oncol"},{"key":"2051_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, Zhang C, Lunceford JK, Joe A, Cheng J, Webber AL, Ibrahim N, Plimack ER, Ott PA, Seiwert TY, Ribas A, McClanahan TK, Tomassini JE, Loboda A, Kaufman D. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018. \n                    https:\/\/doi.org\/10.1126\/science.aar3593\n                    \n                  .","journal-title":"Science"},{"key":"2051_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar3342","author":"SJ Rodig","year":"2018","unstructured":"Rodig SJ, Gusenleitner D, Jackson DG, Gjini E, Giobbie-Hurder A, Jin C, Chang H, Lovitch SB, Horak C, Weber JS, Weirather JL, Wolchok JD, Postow MA, Pavlick AC, Chesney J, Hodi FS. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci Transl Med. 2018. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.aar3342\n                    \n                  .","journal-title":"Sci Transl Med"},{"key":"2051_CR18","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, Piha-Paul SA, Yearley J, Seiwert TY, Ribas A, McClanahan TK. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930\u201340. \n                    https:\/\/doi.org\/10.1172\/JCI91190\n                    \n                  .","journal-title":"J Clin Invest"},{"key":"2051_CR19","doi-asserted-by":"publisher","first-page":"P80","DOI":"10.1186\/2051-1426-3-S2-P80","volume":"3","author":"M Ayers","year":"2015","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Albright A, Cheng J, Kang SP, Ebbinghaus S, Yearley J, Shankaran V, Seiwert T, Ribas A, McClanahan T. Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors. J Immunother Cancer. 2015;3:P80. \n                    https:\/\/doi.org\/10.1186\/2051-1426-3-S2-P80\n                    \n                  .","journal-title":"J Immunother Cancer"},{"key":"2051_CR20","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1001\/jama.2017.12131","volume":"318","author":"H Husain","year":"2017","unstructured":"Husain H, Velculescu VE. Cancer DNA in the circulation: the liquid biopsy. JAMA. 2017;318:1272\u20134. \n                    https:\/\/doi.org\/10.1001\/jama.2017.12131\n                    \n                  .","journal-title":"JAMA"},{"key":"2051_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41698-017-0039-5","volume":"1","author":"E Heitzer","year":"2017","unstructured":"Heitzer E, Perakis S, Geigl JB, Speicher MR. The potential of liquid biopsies for the early detection of cancer. NPJ Precis Oncol. 2017;1:36. \n                    https:\/\/doi.org\/10.1038\/s41698-017-0039-5\n                    \n                  .","journal-title":"NPJ Precis Oncol"},{"key":"2051_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fmed.2018.00009","volume":"5","author":"IB Hench","year":"2018","unstructured":"Hench IB, Hench J, Tolnay M. Liquid biopsy in clinical management of breast, lung, and colorectal cancer. Front Med. 2018;5:9. \n                    https:\/\/doi.org\/10.3389\/fmed.2018.00009\n                    \n                  .","journal-title":"Front Med"},{"key":"2051_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejca.2017.04.022","volume":"81","author":"R Bernab\u00e9","year":"2017","unstructured":"Bernab\u00e9 R, Hickson N, Wallace A, Blackhall FH. What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer? Eur J Cancer. 2017;81:66\u201373. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2017.04.022\n                    \n                  .","journal-title":"Eur J Cancer"},{"key":"2051_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11912-018-0720-z","volume":"20","author":"JWP Bracht","year":"2018","unstructured":"Bracht JWP, Mayo-de-Las-Casas C, Berenguer J, Karachaliou N, Rosell R. The present and future of liquid biopsies in non-small cell lung cancer: combining four biosources for diagnosis, prognosis, prediction, and disease monitoring. Curr Oncol Rep. 2018;20:70. \n                    https:\/\/doi.org\/10.1007\/s11912-018-0720-z\n                    \n                  .","journal-title":"Curr Oncol Rep"},{"key":"2051_CR25","doi-asserted-by":"publisher","DOI":"10.1200\/po.16.00009","author":"SQ Wong","year":"2017","unstructured":"Wong SQ, Raleigh JM, Callahan J, Vergara IA, Ftouni S, Hatzimihalis A, Colebatch AJ, Li J, Semple T, Doig K, Mintoff C, Sinha D, Yeh P, Silva MJ, Alsop K, Thorne H, Bowtell DD, Gyorki DE, Arnau GM, Cullinane C, Kee D, Brady B, Kelleher F, Dawson MA, Papenfuss AT, Shackleton M, Hicks RJ, McArthur GA, Sandhu S, Dawson S-J. Circulating tumor DNA analysis and functional imaging provide complementary approaches for comprehensive disease monitoring in metastatic melanoma. JCO Precis Oncol. 2017. \n                    https:\/\/doi.org\/10.1200\/po.16.00009\n                    \n                  .","journal-title":"JCO Precis Oncol"},{"key":"2051_CR26","doi-asserted-by":"publisher","first-page":"8839","DOI":"10.1038\/ncomms9839","volume":"6","author":"L De Mattos-Arruda","year":"2015","unstructured":"De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Mart\u00ednez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Mart\u00ednez-S\u00e1ez E, Lois S, Mar\u00edn O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramon y Cajal S, Carles J, Rodon J, Gonz\u00e1lez-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839. \n                    https:\/\/doi.org\/10.1038\/ncomms9839\n                    \n                  .","journal-title":"Nat Commun"},{"key":"2051_CR27","doi-asserted-by":"publisher","first-page":"e000270","DOI":"10.1136\/esmoopen-2017-000270","volume":"2","author":"L De Mattos-Arruda","year":"2017","unstructured":"De Mattos-Arruda L. Liquid biopsy for HER2-positive breast cancer brain metastasis: the role of the cerebrospinal fluid. ESMO Open. 2017;2:e000270. \n                    https:\/\/doi.org\/10.1136\/esmoopen-2017-000270\n                    \n                  .","journal-title":"ESMO Open"},{"key":"2051_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000486568","volume":"11","author":"W-T Huang","year":"2018","unstructured":"Huang W-T, Lu N-M, Hsu W-Y, Chang S-E, Atkins A, Mei R, Javey M. CSF-ctDNA SMSEQ analysis to tailor the treatment of a patient with brain metastases: a case report. Case Rep Oncol. 2018;11:68\u201374. \n                    https:\/\/doi.org\/10.1159\/000486568\n                    \n                  .","journal-title":"Case Rep Oncol"},{"key":"2051_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/po.17.00054","author":"AP Singh","year":"2017","unstructured":"Singh AP, Cheng H, Guo X, Levy B, Halmos B. Circulating tumor DNA in non-small-cell lung cancer: a primer for the clinician. JCO Precis Oncol. 2017. \n                    https:\/\/doi.org\/10.1200\/po.17.00054\n                    \n                  .","journal-title":"JCO Precis Oncol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-2051-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-019-2051-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-2051-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T23:18:33Z","timestamp":1599175113000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-019-2051-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2051"],"URL":"https:\/\/doi.org\/10.1186\/s12967-019-2051-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]},"assertion":[{"value":"16 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Blood samples were prospectively collected after obtaining informed consent with an Ethical Committee (UZ Brussel) approved document.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All parties consented for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"303"}}